Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.97 +1.0%	$11.78	$3.98 ▼ $13.52	$1.97B	1.93	2.01 million shs	608,228 shs
ANIP ANI Pharmaceuticals	$93.59 -0.5%	$74.48	$52.50 ▼ $95.60	$2.04B	0.63	372,638 shs	108,638 shs
BCYC Bicycle Therapeutics	$7.15 -0.7%	$7.66	$6.10 ▼ $28.67	$494.10M	1.41	315,393 shs	96,577 shs
RXRX Recursion Pharmaceuticals	$4.61 -1.2%	$5.43	$3.79 ▼ $12.36	$2.00B	0.91	24.27 million shs	6.61 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-2.58%	+0.31%	+24.30%	+28.66%	+173.19%
ANIP ANI Pharmaceuticals	+0.64%	+2.41%	+47.19%	+54.59%	+47.61%
BCYC Bicycle Therapeutics	-2.44%	+3.00%	-9.89%	-14.89%	-66.51%
RXRX Recursion Pharmaceuticals	-0.85%	-3.52%	-17.96%	-5.09%	-35.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.3034 of 5 stars	1.4	3.0	4.2	3.5	1.7	0.6
ANIP ANI Pharmaceuticals	3.6771 of 5 stars	1.6	2.0	3.3	4.1	3.3	1.3
BCYC Bicycle Therapeutics	2.8811 of 5 stars	3.4	3.0	0.0	2.5	2.5	0.6
RXRX Recursion Pharmaceuticals	2.1027 of 5 stars	3.2	1.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.55% Downside
ANIP ANI Pharmaceuticals	3.10	Buy	$84.75	-9.45% Downside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$22.22	210.80% Upside
RXRX Recursion Pharmaceuticals	2.40	Hold	$7.25	57.44% Upside

Current Analyst Ratings Breakdown

Latest BCYC, RXRX, ANIP, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	ANIP ANI Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $10.00
8/12/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $13.00
8/11/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$27.00
8/11/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$65.00 ➝ $77.00
8/11/2025	BCYC Bicycle Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $44.00
8/8/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $93.00
8/8/2025	ANIP ANI Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$94.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	11.03	N/A	N/A	$1.18 per share	10.99
ANIP ANI Pharmaceuticals	$614.38M	3.31	$7.60 per share	12.31	$20.13 per share	4.65
BCYC Bicycle Therapeutics	$35.28M	14.03	N/A	N/A	$9.66 per share	0.74
RXRX Recursion Pharmaceuticals	$58.84M	33.98	N/A	N/A	$2.12 per share	2.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
ANIP ANI Pharmaceuticals	-$18.52M	-$0.77	N/A	22.23	N/A	-1.37%	25.03%	8.00%	11/14/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.51	N/A	N/A	N/A	-1,257.00%	-32.43%	-26.80%	10/30/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)

Latest BCYC, RXRX, ANIP, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.42	$1.80	+$0.38	$0.36	$187.18 million	$211.37 million
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
ANIP ANI Pharmaceuticals	1.39	2.54	1.96
BCYC Bicycle Therapeutics	N/A	10.39	10.39
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ANIP ANI Pharmaceuticals	76.05%
BCYC Bicycle Therapeutics	86.15%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ANIP ANI Pharmaceuticals	12.70%
BCYC Bicycle Therapeutics	8.50%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
ANIP ANI Pharmaceuticals	600	21.70 million	18.94 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.37 million	Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable

BCYC, RXRX, ANIP, and ADPT Headlines

Recent News About These Companies

Jump Financial LLC Increases Position in Recursion Pharmaceuticals, Inc. $RXRX

August 29, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition

August 28, 2025 | insidermonkey.com

Recursion to Participate in Upcoming Investor Conferences

August 27, 2025 | globenewswire.com

Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Organogenesis (NASDAQ:ORGO)

August 27, 2025 | americanbankingnews.com

1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

August 25, 2025 | marketbeat.com

Needham Maintains Buy Rating on Recursion (RXRX)

August 24, 2025 | msn.com

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode

August 23, 2025 | fool.com

Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

August 23, 2025 | marketbeat.com

Why Recursion Pharmaceuticals Stock Caught a Cold This Week

August 22, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025

August 22, 2025 | finance.yahoo.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

August 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

August 21, 2025 | insidermonkey.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's Why

August 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 Shares

August 20, 2025 | insidertrades.com

EverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

August 19, 2025 | seekingalpha.com

Liontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

August 17, 2025 | insidermonkey.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, RXRX, ANIP, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.96 +0.13 (+0.97%)

As of 12:38 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ANI Pharmaceuticals NASDAQ:ANIP

$93.59 -0.51 (-0.54%)

As of 12:37 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Bicycle Therapeutics NASDAQ:BCYC

$7.15 -0.05 (-0.69%)

As of 12:37 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.61 -0.06 (-1.18%)

As of 12:38 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time